Celldex Therap

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a Net Loss of $73.5M vs. an expected $82.0M, resulting in an EPS GAAP of -$0.94, which beat the expected -$1.06 due to a higher-than-anticipated share count following an April public offering. Revenue remains immaterial at $0.02M, significantly below the $0.86M consensus as services for Rockefeller University decreased. Despite the top-line miss, the company strengthened its balance sheet to $717.6M in cash, extending the runway through 2028, while narrowing focus by discontinuing the failed Prurigo Nodularis program.